Home / Stocks / INCY

Incyte (INCY, Biotechnology) Stock Valuation & Fair Value High quality, attractively priced for its growth

Incyte (INCY, Biotechnology) trades at a blended P/E of 27.2, about 49% below its historical normal valuation, with a forward growth estimate of 31.0% and a PEG of 0.88. Analysts' one-year estimates have been hit 9% of the time.

DATA AS OF 2026-08-21
Blended P/E
27.2
Normal P/E
53.2
PEG
0.88
Fwd growth
31.0%
Div yield
0.0%
RSI (14)
60.6
Neutral

The Street vs SeerForecast

Wall Street's mean price target for INCY is $125.17 across 23 analysts, 2.1% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: high quality, attractively priced for its growth. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from quality business with a solid forward outlook (2026-06-10) to high quality, attractively priced for its growth (2026-08-21).

Price and rating by weekClose moved +14.0 percent from 2026-06-10 to 2026-08-17, with 2 rating changes over 20 recorded weeks.2026-06-10: Quality business with a solid forward outlook, close 105.39 (recalculated)2026-06-14: Quality business with a solid forward outlook, close 108.53 (recalculated)2026-06-16: Quality business with a solid forward outlook, close 99.75 (recalculated)2026-06-21: Quality business with a solid forward outlook, close 98.22 (recalculated)2026-07-02: Fairly valued, close 116.86 (recalculated)2026-07-06: Fairly valued, close 115.62 (recalculated)2026-07-09: Fairly valued, close 118.52 (recalculated)2026-07-12: Fairly valued, close 116.71 (recalculated)2026-07-13: Fairly valued, close 114.23 (recalculated)2026-07-14: Fairly valued, close 114.88 (recalculated)2026-07-20: Fairly valued, close 115.65 (recalculated)2026-07-22: Fairly valued, close 115.79 (recalculated)2026-07-25: Fairly valued, close 117.67 (recalculated)2026-07-27: Fairly valued, close 118.87 (recalculated)2026-07-31: High quality, attractively priced for its growth, close 119.52 (recalculated)2026-08-03: High quality, attractively priced for its growth, close 119.522026-08-07: High quality, attractively priced for its growth, close 120.56 (recalculated)2026-08-10: High quality, attractively priced for its growth, close 120.562026-08-14: High quality, attractively priced for its growth, close 120.16 (recalculated)2026-08-17: High quality, attractively priced for its growth, close 120.161051202026-06-102026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-10P/E 14.3-73%Quality business with a solid forward outlook
2026-06-14P/E 14.3-73%Quality business with a solid forward outlook
2026-06-16P/E 14.3-73%Quality business with a solid forward outlook
2026-06-21P/E 14.3-73%Quality business with a solid forward outlook
2026-07-02P/E 15.7-71%Fairly valued
2026-07-06P/E 16.1-70%Fairly valued
2026-07-09P/E 16.1-70%Fairly valued
2026-07-12P/E 16.0-70%Fairly valued
2026-07-13P/E 16.0-70%Fairly valued
2026-07-14P/E 16.0-70%Fairly valued
2026-07-20P/E 15.9-70%Fairly valued
2026-07-22P/E 15.9-70%Fairly valued
2026-07-25P/E 15.9-70%Fairly valued
2026-07-27P/E 15.9-70%Fairly valued
2026-07-31P/E 24.1-55%High quality, attractively priced for its growth
2026-08-03P/E 23.5-56%High quality, attractively priced for its growth
2026-08-07P/E 23.5-56%High quality, attractively priced for its growth
2026-08-10P/E 23.9-55%High quality, attractively priced for its growth
2026-08-14P/E 24.7-54%High quality, attractively priced for its growth
2026-08-17P/E 24.7-54%High quality, attractively priced for its growth
2026-08-21P/E 27.2-49%High quality, attractively priced for its growth ← now

Frequently asked questions

Is Incyte stock overvalued?

At a blended P/E of 27.2 versus its historical normal P/E of 53.2, Incyte trades about 49% below its typical valuation, with a PEG of 0.88 on 31.0% forward growth. tickerseer currently rates it high quality, attractively priced for its growth.

What is Incyte's fair value and PEG?

Incyte trades at a blended P/E of 27.2 against a historical normal P/E of 53.2, a PEG of 0.88, and a forward growth estimate of 31.0%.

Has tickerseer's rating of Incyte changed?

tickerseer's rating moved from quality business with a solid forward outlook (2026-06-10) to high quality, attractively priced for its growth (2026-08-21).

What is the analyst price target for Incyte?

The mean Wall Street price target for Incyte is $125.17 across 23 analysts, 2.1% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track INCY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.